Joseph E. Glass, PhD, MSW

Glass_Joseph_E_205x287.jpg

“We need to increase the reach of addiction treatment within health care systems. Many more people could benefit from effective care.”

Joseph E. Glass, PhD, MSW

Senior Scientific Investigator, Kaiser Permanente Washington Health Research Institute
Affiliate Associate Professor, Department of Health Systems and Population Health, Department of Psychiatry and Behavioral Sciences, University of Washington

Biography

Joseph Glass, PhD, MSW, is an associate investigator at Kaiser Permanente Washington Health Research Institute (KPWHRI). Before joining KPWHRI in July 2016, he was an assistant professor at the University of Wisconsin–Madison School of Social Work.

Dr. Glass’s research seeks to identify how effective health care interventions for unhealthy alcohol and drug use can reach more people. Much of his work aims to develop, test, and implement modern models of care that proactively deliver evidence-based treatments within health care settings and that intensively refer patients to specialty care while considering social determinants of health.

Dr. Glass’s work is informed by his practical experience in the field. After receiving a Master of Social Work from the University of Michigan, Dr. Glass was a psychiatric social worker at the Veterans Affairs Ann Arbor Healthcare System. There he developed expertise in social work case management and evidence-based treatments for anxiety, depression, and substance use disorders.

He completed a 5-year career development award funded by the National Institute on Alcohol Abuse and Alcoholism in 2021, which allowed him to obtain intensive training in clinical trials and implementation science. Currently, he has 2 active randomized controlled trials.

  • One is a 5-year grant awarded by the National Institute on Drug Abuse called the DIGITS Trial, which is testing strategies for improving how clinicians and patients use app-based treatments for substance use disorder in primary care.
  • Another study is the Addressing Barriers to Care Trial (ABC-SUD), which is a 5-year grant awarded by the National Institute on Drug Abuse as part of the Center for Dissemination and Implementation Science at Stanford. The ABC-SUD study is evaluating use of Care Navigators to improve the rate at which people successfully obtain treatment when they are referred to care.

Dr. Glass also co-leads a 2-year study funded by the National Institute on Alcohol Abuse and Alcoholism to validate and improve approaches for monitoring the quality of care for alcohol use disorder. He also enjoys serving as a co-investigator and consultant, providing expertise and support to studies led by his colleagues.

Dr. Glass is an affiliate associate professor of health systems and population health, and of psychiatry and behavioral sciences, at the University of Washington.​​​​​

Research interests and experience


Sparc trial tools

Resources for behavioral health integration

The SPARC trial successfully implemented behavioral health care into primary care. On our website, you can access tools for behavioral health integration, as well as frequently asked questions and publications.


Recent publications

Brown R, Deyo B, Riley C, Quanbeck A, Glass JE, Turpin R, Hetzel S, Nicholas C, Cruz M, Agarwal S. Screening in Trauma for Opioid Misuse Prevention (STOMP): study protocol for the development of an opioid risk screening tool for victims of injury. Addict Sci Clin Pract. 2017;12(1):28. doi: 10.1186/s13722-017-0097-6.  PubMed

Williams EC, Gupta S, Rubinsky AD, Glass JE, Jones-Webb R, Bensley KM, Harris AHS. Variation in receipt of pharmacotherapy for alcohol use disorders across racial/ethnic groups: A national study in the U.S. Veterans Health Administration.  Drug Alcohol Depend. 2017 Sep 1;178:527-533. doi: 10.1016/j.drugalcdep.2017.06.011. Epub 2017 Jul 11.  PubMed

Lehavot K, Blosnich JR, Glass JE, Williams EC. Alcohol use and receipt of alcohol screening and brief intervention in a representative sample of sexual minority and heterosexual adults receiving health care.  Drug Alcohol Depend. 2017 Oct 1;179:240-246. doi: 10.1016/j.drugalcdep.2017.07.003. Epub 2017 Aug 2. PubMed

Busch AC, Shivaram M, Glass JE, Hetzel S, Gugani SP, Gassman M, Krahn D, Deyo B, Brown RT. Pre-discharge injectable vs. oral naltrexone to improve post-discharge treatment engagement among hospitalized veterans with alcohol use disorder: a pilot proof-of-concept study. Alcohol Clin Exp Res. 2017 Jul;41(7):1352-1360. doi: 10.1111/acer.13410. Epub 2017 Jun 12. PubMed

Busch AC, Denduluri M, Glass J, Hetzel S, Gugnani SP, Gassman M, Krahn D, Deyo B, Brown R. Predischarge injectable versus oral naltrexone to improve postdischarge treatment engagement among hospitalized veterans with alcohol use disorder: a randomized pilot proof-of-concept study. Alcohol Clin Exp Res. 2017 Jul;41(7):1352-1360. doi: 10.1111/acer.13410. Epub 2017 Jun 12. PubMed

 

Healthy Findings Blog

ABC-Study_JoeGlass_QA_1col.jpg

Understanding the needs of people seeking care for substance use

Joe Glass explores how to engage patients with treatment for alcohol or drug use.

Research

PROUD_trial_1col.jpg

Increasing opioid use disorder treatment in primary care

A trial led by KPWHRI researchers found that adding nurse care managers helped more people get needed treatment.

Research

SPARC-study_story_blog_1col.jpg

Better care for patients who drink alcohol

A new primary care approach improves alcohol-related preventive care as well as care for alcohol use disorder.